Company news

Aligos Therapeutics, Inc. news in 2024

Aligos Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

November 18, 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

November 5, 2024

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

October 21, 2024

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

October 14, 2024

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

September 30, 2024

Aligos Therapeutics to Present at Investor Conferences in October

September 29, 2024

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

September 23, 2024

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

September 18, 2024

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

September 17, 2024

Aligos Therapeutics Announces Reverse Stock Split

August 14, 2024

Aligos Therapeutics Strengthens Board with Two New Independent Directors

August 7, 2024

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

August 5, 2024

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

July 21, 2024

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

July 9, 2024

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

May 20, 2024

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

May 6, 2024

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

April 29, 2024

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

April 24, 2024

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

April 2, 2024

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

March 26, 2024

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

March 17, 2024

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

March 11, 2024

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

March 4, 2024

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

February 12, 2024

Decks in 2024